Start Here — The Short Version
Melasma is chronic, symmetrical facial pigmentation driven by sun exposure, hormones and genetics — most often affecting women, and common in Fitzpatrick III–V skin.
The most useful thing most melasma advice omits: visible light also drives it — ordinary daylight, screens, indoor lighting. And visible light is not blocked by conventional sunscreen, nor measured by SPF or PA ratings. Iron oxides, the pigments in tinted sunscreen, are what block it.
That is why melasma so often persists in people who are diligent with SPF. A trial found tinted sunscreen outperformed non-tinted for preventing relapse, with the same UV filters.
This article is educational and is not medical advice, diagnosis or a treatment recommendation. Melasma is a medical condition — consult a qualified dermatologist for assessment and management, particularly if pregnant, breastfeeding or trying to conceive.
Melasma is one of the most frustrating conditions in dermatology, partly because the standard advice is incomplete in a specific and consequential way.
In This Article
The Basics
What Melasma Is
Melasma is acquired hyperpigmentation appearing as symmetrical brown to greyish-brown patches, most often on the face. Symmetry is the defining feature — pigmentation on one cheek but not the other is usually something else.
All melasma is hyperpigmentation; not all hyperpigmentation is melasma. Sun spots are discrete and asymmetric. Post-inflammatory pigmentation follows the shape of whatever inflamed the skin. Melasma is patterned and symmetrical, typically centrofacial (forehead, cheeks, nose, upper lip), malar (cheekbones), or mandibular (jawline).
Depth matters for what can be done about it. Epidermal pigment sits in the upper layers and responds relatively better to topicals. Dermal pigment sits deeper, often looks greyish, and is considerably more stubborn. Mixed is the most common presentation in deeper skin tones — and the next two sections explain why that distinction turns out to be central.
The Gap In Standard Advice
The Visible Light Problem
Melasma advice is overwhelmingly about UV — broad-spectrum, PA++++, reapply. All correct, and it leaves out something that matters enormously in deeper skin.
What SPF does not measure
Work by Mahmoud and colleagues showed that visible light induces pigmentation in Fitzpatrick IV–VI skin — and that the pigmentation it produces is darker and longer-lasting than that produced by comparable UVA1 exposure. In lighter skin, visible light produced little effect.
Here is the practical problem. SPF measures UVB. PA ratings measure UVA. Neither measures visible light, and conventional transparent sunscreen filters do not block it. You can apply a high-SPF, high-PA sunscreen perfectly and still receive the visible light exposure driving your pigmentation.
What does block it is iron oxides — the pigments that make a sunscreen tinted. Boukari and colleagues ran a randomised comparison in women with melasma: same UV filters, tinted versus non-tinted. The tinted group had significantly fewer relapses.
This reframes a common and demoralising experience. People with melasma who are genuinely diligent about sunscreen, and see it persist anyway, are frequently not failing at anything — they have been protecting against two of the three relevant wavelength ranges.
It also explains why melasma can hold steady through an Indian winter and why office workers are not exempt. Visible light comes through windows, and indoor lighting and screens contribute — though outdoor daylight remains by far the dominant exposure.
What to look for on a label
Iron oxides in the ingredient list — usually appearing as CI 77491, CI 77492 and CI 77499. A sunscreen with a tint that suits your skin tone is doing something a transparent one cannot, regardless of its SPF.
This is one of the few places where a cosmetically tinted product has a genuine mechanistic advantage rather than a marketing one — and where the shade range available in India for deeper skin tones is a real and legitimate frustration.
Heat is worth naming separately. Infrared and ambient heat are implicated in pigmentation independently of UV, which matters near cooking, during Indian summers, and around any sustained heat exposure. It is not a substitute for sun protection, but it explains flares that do not track with sun exposure alone.
The Mechanism
Why It Comes Back
Melasma is described as chronic and recurrence-prone, usually without explaining why. There is a mechanism, and understanding it changes what expectations are reasonable.
Not just a melanocyte problem
The basement membrane is damaged. The layer separating epidermis from dermis shows disruption in melasma lesional skin. That allows melanin, and sometimes melanocytes themselves, to drop into the dermis — where topical treatments cannot reach it and where clearance is extremely slow.
Lesions are more vascular. Melasma skin shows increased number and size of blood vessels, and that vascular component appears to interact with pigment production rather than sitting passively alongside it.
So melasma is a change in the skin's environment, not only in its pigment cells. Suppressing melanin production addresses one component. The damaged membrane and altered vasculature persist — which is precisely why pigmentation returns when treatment stops.
Two useful consequences follow. First, maintenance is not a failure of the treatment — it is the appropriate response to a condition where the underlying substrate remains altered. Second, dermal pigment genuinely responds less to topicals, so slow progress on greyish-toned melasma reflects depth rather than an inadequate product.
The Context
Why It's Common In Indian Skin
Four factors converge, and the fourth is the one the visible-light section explains.
| Factor | Why it matters here |
|---|---|
| Skin type | Melasma is most reported in Fitzpatrick III–V, which describes most Indian skin. Melanocytes here respond readily when triggered. |
| Latitude and climate | Year-round high sun angle rather than seasonal — exposure is continuous, not concentrated into summer. |
| Hormones | Around 90% of cases occur in women; pregnancy and combined contraceptives are recognised triggers. |
| Visible light sensitivity | The compounding factor. Deeper skin responds to visible light with pigmentation that lighter skin does not develop — and standard sunscreen does not address it. |
Family history is common, reported by a substantial share of patients across studies, which is why melasma often runs in families. Genes do not cause it directly — they set how readily melanocytes respond to the triggers above.
Melasma does occur in men, typically around one in ten cases, usually with substantial occupational sun exposure. It is under-recognised in men partly because it is framed as a women's condition.
Management
What Treatment Involves
There is no single best treatment, and anything promising a cure should be treated with suspicion. What the evidence supports is a layered approach, and the layers are not equally weighted.
- Photoprotection, including visible light. The foundation, and the layer most often applied incompletely. Broad-spectrum UV protection plus iron oxides, daily, year-round. Everything else underperforms without it.
- Prescription topicals. Hydroquinone, retinoids and combination formulations have the strongest evidence and are prescription-only for good reason — misuse carries real risks in deeper skin. A dermatologist's territory.
- Supportive cosmetic ingredients. Tranexamic acid, niacinamide, azelaic acid, vitamin C, arbutin and kojic acid have all been studied. Response varies, effects are gradual, and these support rather than replace the layers above.
- Procedures, cautiously. Peels and certain devices are used by dermatologists — and in Fitzpatrick IV–V they carry a genuine risk of making pigmentation worse if wrongly selected. Specialist assessment is not a formality here.
- Trigger review. Discussing hormonal contraception and heat exposure with a clinician addresses inputs no topical reaches.
Why we are not recommending our own products here
Melasma is a medical condition, and cosmetic products are not a treatment for it. Our own clinical study measured pigmentation endpoints, and those endpoints did not reach statistical significance — so recommending our products on a melasma page would be claiming something our own data does not support. The honest answer to melasma is photoprotection that includes visible light, and a dermatologist.
Misconceptions
Misconceptions
FAQ
Frequently Asked Questions
The Bottom Line
If you have melasma and diligent sunscreen has not helped, the likeliest missing piece is visible light — unmeasured by SPF or PA, unblocked by transparent filters, and blocked by iron oxides. And it recurs because the basement membrane is damaged, letting pigment reach a depth topicals cannot follow. Tinted broad-spectrum protection daily, a dermatologist for the rest, and maintenance rather than a cure.
Scientific References
- Mahmoud BH, Ruvolo E, Hexsel CL, et al. Impact of long-wavelength UVA and visible light on melanocompetent skin. Journal of Investigative Dermatology. 2010;130(8):2092–2097.
- Boukari F, Jourdan E, Fontas E, et al. Prevention of melasma relapses with sunscreen combining protection against UV and short wavelengths of visible light: a prospective randomized comparative trial. Journal of the American Academy of Dermatology. 2015;72(1):189–190.e1.
- Torres-Álvarez B, Mesa-Garza IG, Castanedo-Cázares JP, et al. Histochemical and immunohistochemical study in melasma: evidence of damage in the basal membrane. American Journal of Dermatopathology. 2011;33(3):291–295.
- Kim EH, Kim YC, Lee ES, Kang HY. The vascular characteristics of melasma. Journal of Dermatological Science. 2007;46(2):111–116.
- Sanchez NP, Pathak MA, Sato S, Fitzpatrick TB, Sanchez JL, Mihm MC. Melasma: a clinical, light microscopic, ultrastructural, and immunofluorescence study. Journal of the American Academy of Dermatology. 1981;4(6):698–710.
- Handel AC, Miot LDB, Miot HA. Melasma: a clinical and epidemiological review. Anais Brasileiros de Dermatologia. 2014;89(5):771–782.
- Achar A, Rathi SK. Melasma: a clinico-epidemiological study of 312 cases. Indian Journal of Dermatology. 2011;56(4):380–382.
- Ogbechie-Godec OA, Elbuluk N. Melasma: an up-to-date comprehensive review. Dermatology and Therapy. 2017;7(3):305–318.
Note to editor: this list replaces the previous one, in which several entries had journal, volume or year mismatches. Please verify each entry before publication, and only display a reference count that matches the list.
© 2026 Boldpurity · For educational purposes only · Not to be reproduced without permission.